Why IMU is a multi multi bagger, page-21174

Hi Donvan.

Thank you for your kind words.

Yes, CRISPR-Cas9 is stunning science, and has already gleaned a Nobel Prize for chemistry. What part it might place in IMU’s future is yet to be revealed.

If you are looking for clever science that may well impact on IMU cancer targets then look no further than RenovoRx. We have recently signed a collaboration here.

It is clear that IMU will chase GI cancers, and in the case of Rx’s TAMP technology capabilities, we would first look at Bile Duct and Pancreatic cancers I suspect. This Trans-Arterial Micro-Perfusion (TAMPTM) therapy platform is designed to ensure precise therapeutic delivery, directly to the target tumour. Can you imagine what Vaxinia, for example, might achieve at high dose, if it is able to be delivered exactly to the tumour every time. I think I can guess ... ‘game over’ for that cancer.

Thank you ‘xr’ too.

Thanks to Ben and T-Bull for your comments also. Your commentary is always thought-provoking, and certainly widens the debate around IMU going forward.

As always, opinion only.